Eye injection showdown: which drug restores vision better in diabetes patients?
NCT ID NCT07338097
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares two common eye injection drugs, aflibercept and bevacizumab, in adults aged 30-60 with diabetic macular edema (fluid buildup in the retina causing vision loss). About 116 participants will receive monthly injections for two months. The goal is to see which drug improves vision more and reduces retinal swelling. This is not a cure but aims to ease symptoms and improve sight.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETIC MACULAR EDEMA (DME) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CMH Institute of Medical Sciences
Multan, Punjab Province, 66000, Pakistan